Richard King is the founder of Spruce Biosciences. Spruce Biosciences has raised $88M in total funding. Latest round: Series B.
Richard King is the CEO of Spruce Biosciences, a clinical-stage biotechnology company developing and commercializing therapies for rare endocrine disorders. Spruce’s lead program is tildacerfont, an investigational oral drug for congenital adrenal hyperplasia (CAH).
Full founder directory · Investor directory · Company funding database · Fundraising library